Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219914
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial. Here we report updated outcomes of patients with NHL treated with var-cel. B-cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty-five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade ≥3) and neurotoxicity in 7% (2% grade ≥3). The objective response rate was 73% at Day +100, and the 3-year duration of response was 56%. The 3-year progression-free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression-free survival. The 3-year incidence of B-cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var-cel was manageable, while B-cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583.
Matèries
Matèries (anglès)
Citació
Citació
MARTÍNEZ CIBRIÁN, Núria, ORTIZ MALDONADO, Valentín, ESPAÑOL REGO, Marta, BLÁZQUEZ, Andrea, CID, Joan, LOZANO, Miquel, MAGNANO, Laura, GINÉ SOCA, Eva, CORREA, Juan g., MOZAS, Pablo, RODRÍGUEZ LOBATO, Luis gerardo, RIVERO, Andrea, MONTORO LORITE, Mercedes, AYORA, Pilar, NAVARRO, Sergio, ALSERAWAN, Leticia, GONZÁLEZ NAVARRO, Europa azucena, CASTELLÀ CASTELLÀ, Maria, SÁNCHEZ CASTAÑÓN, María, CABEZÓN, Raquel, BENÍTEZ-RIBAS, Daniel, SETOAÍN, Xavier, RODRÍGUEZ, Sonia, BRILLEMBOURG, Helena, VAREA, Sara, OLESTI MUÑOZ, Eulàlia, GUILLÉN, Elena, SÁEZ PEÑATARO, Joaquín, FERNÁNDEZ DE LARREA, Carlos, LÓPEZ GUILLERMO, Armando, PASCAL, Mariona, URBANO ISPIZUA, Álvaro, JUAN, Manel, DELGADO, Julio. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. _British Journal of Haematology_. 2024. Vol. 204, núm. 2, pàgs. 525-533. [consulta: 21 de gener de 2026]. ISSN: 0007-1048. [Disponible a: https://hdl.handle.net/2445/219914]